Company intelligence / Profile preview

Sachi Enterprises

Ownership: Private
Development stage: Other

Overview

The company has developed Nanoligomer treatments described as “game-changing” tools against Alzheimer’s, dementia, and aging. They have won awards such as the US National Academy of Medicine Sponsored Healthy Longevity Global Challenge for Healthy Aging. Their technology has been tested in advanced models including brain organoids sent to space via SpaceX CRS missions.

Therapeutic areas: OncologyImmunologyOtherNeurologyInfectious Diseases
Modalities: RNA TherapeuticsProgrammable RNA TherapyNucleic acid molecules
Industry: Biotech

Beyond the preview

Go deeper on Sachi Enterprises.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sachi Enterprises.

Explore the full profile